Nurix Therapeutics (NASDAQ:NRIX) Reaches a New 52-Week High Following Partnership with Roche

Nurix Therapeutics Inc. (NASDAQ:NRIX) reached a new 52-week high of $23.09 on June 24, 2026, after announcing a partnership with Roche for the co-development and commercialization of bexobrutideg, an oral degrader targeting Bruton's tyrosine kinase (BTK). The stock closed at $22.46, up 16.37% on the day.

By Angelica Ballesteros Fri, June 26, 2026 at 6:14 AM GMT+3 2 min read · Yahoo Finance · June 26, 2026, 03:14 UTC

Tickers: $NRIX

Topics: biotech partnership BTK degrader drug Nurix stock movement

Read the full article at Yahoo Finance

More World news

EZCORP Reports Strong Q4 2026 Results with Significant EBITDA and Revenue Growth Motley Fool · November 12, 2026, 18:16 UTC
Sabre Corp Shares Decline Following Travelport Denial of Merger Speculation Seeking Alpha · November 12, 2026, 18:21 UTC
Lufax Reports Third Quarter 2026 Net Loss Amid Rising Credit Impairment Costs Motley Fool · November 12, 2026, 18:15 UTC
Avantor Reports Return to Organic Revenue Growth in Third Quarter 2026 Motley Fool · November 12, 2026, 18:15 UTC
MGP Ingredients Rebrands to Sempreon and Announces Strategic Shift Toward Ready-to-Drink Products Motley Fool · November 12, 2026, 18:15 UTC
ICON Reports Q3 2026 Revenue of $2 Billion and Accelerating Book-to-Bill Ratio Motley Fool · November 12, 2026, 18:15 UTC
Beachbody (BODi) Reduces Annual Revenue Breakeven to $125 Million Amid Strategic Pivot Motley Fool · November 12, 2026, 18:15 UTC
Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC
Nuwellis Reports Q3 2026 Revenue of $2.2 Million and Improved Operating Loss Motley Fool · November 12, 2026, 18:09 UTC
Nebius Group Reports Strong Revenue Growth Amidst Capacity Delays and Increased Capital Expenditure Motley Fool · November 12, 2026, 18:11 UTC